Section 03 · Monograph
Tavapadon
Reviewed Nov 2026FDA label
JuvmoD1/D5 dopamine partial agonist
- Forms
- Tab: 5, 10, 15mg | Titration pack: 0.25, 1mg tabs
- Dose
- Once daily with or without levodopa (monotherapy in early PD or adjunct for motor fluctuations); ~6-week titration to maintenance dose; no label contraindications
- MOA
- Selective D1/D5 receptor partial agonism (CYP3A substrate)
Indications
- Parkinson's disease in adults: monotherapy in early disease and adjunct to levodopa in patients with motor fluctuations (FDA-approved September 2026)FDA-labeled
Mechanism of Action
- Selective D1/D5 dopamine receptor partial agonist, distinct from D2/D3-targeting dopamine agonists
Full Dosing
Adult / usual
- Once-daily oral tablets (5, 10, 15mg) with a titration pack of 0.25mg and 1mg tablets; label titration takes about 6 weeks
Renal
- This is a newly approved product — confirm the exact titration schedule, hepatic/renal adjustments and CYP3A interaction dosing in the current prescribing information
Contraindications
- None listed in labeling
Drug Interactions
- CYP3A substrate: strong CYP3A inhibitors or inducers affect exposure — see label
- Dopamine antagonists may reduce effectiveness
Adverse Effects
- Dopaminergic class effects per label (for example somnolence and sudden sleep onset, nausea, dizziness, hallucinations and impulse-control behaviors) — verify against the current prescribing information
- Patients older than 80 years were excluded from pivotal trials
Monitoring Parameters
- Daytime sleepiness, orthostatic blood pressure, psychiatric and impulse-control symptoms
- Motor fluctuations and levodopa dose
Pregnancy & Lactation
- Limited data; confirm in current prescribing information